Clinical Trial Update: Azacytidine Plus FLAG for Relapsed or Refractory AML [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating azacitidine plus FLAG for relapsed or refractory acute myeloid leukemia; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Cytarabine (Ara-C) (cytarabine)
• Filgrastim (filgrastim)
• Fludarabine (Fludarabine)

Snippet

Sponsor: King Fahad Medical City | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: UNKNOWN